FDA Approves 's Cervista HTA System (Hologic) for Cervical Cancer screening

The FDA has approved the Cervista HTA (high throughput automation) system, from Hologic Inc, for use with the company's previously approved Cervista human papillomavirus (HPV) HR test. The Cervista HPV HR test utilizes Hologic's Invader technology to detect 14 high risk types of HPV that are associated with Cervical Cancer and precancerous lesions. The Cervista HTA system automates the DNA extraction and detection steps of the Hologic Cervista HPV HR test.